What changed from existing technology?
This study looked at how a blood test called the CNP index relates to the chance of dying in patients with pneumonia who are taking steroids. The results suggest that higher CNP values might mean a higher risk of death within 30 or 90 days.
This study is the first to examine the association between the CNP index and mortality risk specifically in patients with pneumonia receiving glucocorticoid therapy, which is a novel application of this composite biomarker.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
Association of the CNP index with mortality risk in patients with pneumonia receiving glucocorticoid therapy. As a composite index for severe infection, th
Title ↗predicting mortality in specific patient populations remains unclear. This study evaluated the association between the CNP index and mortality
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The CNP index may be useful as a prognostic marker to identify pneumonia patients receiving glucocorticoid therapy who are at higher risk of mortality, potentially guiding clinical decision-making.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.